Abstract：
OBJECTIVE: Matrin 3 (MATR3) is a nuclear matrix protein involved in mRNA stabilization, nuclear retention of hyper-edited RNAs, and RNA splicing. The role of MATR3 in cancer is still unclear. The present study aimed to investigate expression levels and prognostic significance of MATR3 in stage I and II non-small cell lung cancer (NSCLC) patients.
METHODS: We examined MATR3 protein immunohistochemically in tumoral and non-tumoral tissue sections from n = 67 NSCLC patients treated at hospital, and MATR3 mRNA from The Cancer Genome Atlas (TCGA) cohort with respect to valid prognostic and predictive features, as well as treatment outcome.
RESULTS: Significantly higher immunohistochemical levels of MATR3 protein were found in tumor-adjacent tissue compared to cancer (p = 0.049). A decrease in MATR3 protein expression was found to be a significant independent adverse prognostic factor for patients overall survival (p = 0.007). By contrast, we observed higher MATR3 mRNA levels in tumoral tissue compared to control lung tissues (p < 0.001). Based on the TCGA dataset, we reported that high MATR3 mRNA level was significantly associated with worse OS of NSCLC patients (p < 0.001); however, it was not an independent prognostic marker (p = 0.156). The discrepancies in prognostic significance of MATR3 gene mRNA and protein levels imply a need for further investigation.
CONCLUSIONS: In conclusion, the present study warrants further investigation into the biological and prognostic value of MATR3 as a potential prognostic marker in early-stage NSCLC patients.
METHODS: We examined MATR3 protein immunohistochemically in tumoral and non-tumoral tissue sections from n = 67 NSCLC patients treated at hospital, and MATR3 mRNA from The Cancer Genome Atlas (TCGA) cohort with respect to valid prognostic and predictive features, as well as treatment outcome.
RESULTS: Significantly higher immunohistochemical levels of MATR3 protein were found in tumor-adjacent tissue compared to cancer (p = 0.049). A decrease in MATR3 protein expression was found to be a significant independent adverse prognostic factor for patients overall survival (p = 0.007). By contrast, we observed higher MATR3 mRNA levels in tumoral tissue compared to control lung tissues (p < 0.001). Based on the TCGA dataset, we reported that high MATR3 mRNA level was significantly associated with worse OS of NSCLC patients (p < 0.001); however, it was not an independent prognostic marker (p = 0.156). The discrepancies in prognostic significance of MATR3 gene mRNA and protein levels imply a need for further investigation.
CONCLUSIONS: In conclusion, the present study warrants further investigation into the biological and prognostic value of MATR3 as a potential prognostic marker in early-stage NSCLC patients.
摘要：
目的：Matrin3（MATR3）是参与mRNA稳定的核基质蛋白，超编辑RNA的核保留，和RNA剪接。MATR3在癌症中的作用尚不清楚。本研究旨在探讨MATR3在I和II期非小细胞肺癌（NSCLC）患者中的表达水平和预后意义。
方法：我们检测了在医院接受治疗的n=67例NSCLC患者的肿瘤和非肿瘤组织切片中的MATR3蛋白免疫组织化学，和MATR3mRNA来自癌症基因组图谱（TCGA）队列，关于有效的预后和预测特征，以及治疗结果。
结果：与癌症相比，癌旁组织中MATR3蛋白的免疫组织化学水平明显更高（p=0.049）。发现MATR3蛋白表达的降低是患者总体生存的显著的独立不良预后因素(p=0.007)。相比之下,与对照肺组织相比,我们在肿瘤组织中观察到更高的MATR3mRNA水平(p<0.001)。基于TCGA数据集,我们报道了高MATR3mRNA水平与NSCLC患者OS恶化显著相关(p<0.001);它不是独立的预后标志物(p=0.156).MATR3基因mRNA和蛋白质水平的预后意义差异意味着需要进一步研究。
结论：结论：本研究需要进一步研究MATR3作为早期NSCLC患者潜在预后标志物的生物学和预后价值.
方法：我们检测了在医院接受治疗的n=67例NSCLC患者的肿瘤和非肿瘤组织切片中的MATR3蛋白免疫组织化学，和MATR3mRNA来自癌症基因组图谱（TCGA）队列，关于有效的预后和预测特征，以及治疗结果。
结果：与癌症相比，癌旁组织中MATR3蛋白的免疫组织化学水平明显更高（p=0.049）。发现MATR3蛋白表达的降低是患者总体生存的显著的独立不良预后因素(p=0.007)。相比之下,与对照肺组织相比,我们在肿瘤组织中观察到更高的MATR3mRNA水平(p<0.001)。基于TCGA数据集,我们报道了高MATR3mRNA水平与NSCLC患者OS恶化显著相关(p<0.001);它不是独立的预后标志物(p=0.156).MATR3基因mRNA和蛋白质水平的预后意义差异意味着需要进一步研究。
结论：结论：本研究需要进一步研究MATR3作为早期NSCLC患者潜在预后标志物的生物学和预后价值.
